Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

elotuzumab

- PMLiVE

Pfizer buys gene therapy specialist Bamboo

Expands pipeline with Duchenne muscular dystrophy candidate in deal worth $700m

- PMLiVE

Pfizer closes on Xeljanz filing in ulcerative colitis

Latest positive data could help the slow-growing drug meet blockbuster sales expectations

Bristol-Myers Squibb (BMS) building

NICE finalises record-breaking Opdivo/Yervoy appraisal

BMS’s immunotherapy combination receives recommendation in 24 days

- PMLiVE

Tau protein drug fails late-stage trial

Alzheimer’s disease therapy only showed benefit in patients with no existing treatments

- PMLiVE

Celgene disappointed as Revlimid fails lymphoma trial

Study shows improvement in progression-free survival but no overall survival rate benefit

- PMLiVE

BMS appoints oncology development head

Dr Fouad Namouni promoted from head of medical

- PMLiVE

Brain training ‘could cut dementia risk’, says study

Findings suggest computerised speed of processing training can reduce cognitive decline by 48 percent

Boehringer Ingelheim headquarters

Boehringer stops Gilotrif head and neck cancer trials

Trial data suggests the drug is “highly unlikely” to prolong patients’ remission

EU flag

EU proposes reforms to make first-in-human trials safer

New guideline revision paper “takes into account lessons learnt” from fatal Bial trial

Roche Basel Switzerland

Roche says Tecentriq “off to a good start”

Bladder cancer therapy drug seems set for rapid growth

Celgene building

Jounce bags $225m upfront in Celgene immuno-oncology deal

Five pipeline candidate agreement worth up to $2.5bn should Celgene claim the rights

- PMLiVE

Alzheimer’s: the numbers we cannot forget

In this article, Consultant David Cooney explores the success rate of trials in AD and the reasons for this incredulous situation, as well as looking at the some of the...

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links